ChiCTR2600123262 版本V1.0 版本创建时间2026/04/23 10:45:25 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123262 

最近更新日期:

Date of Last Refreshed on:

2026-04-23 10:45:09 

注册时间:

Date of Registration:

2026-04-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同模式重复经颅磁刺激对未成年 ADHD 的临床疗效和机制研究

Public title:

Clinical Efficacy and Mechanisms of Different Modes of Repetitive Transcranial Magnetic Stimulation in Minors with ADHD

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同模式重复经颅磁刺激对未成年 ADHD 的临床疗效和机制研究

Scientific title:

Clinical Efficacy and Mechanisms of Different Modes of Repetitive Transcranial Magnetic Stimulation in Minors with ADHD

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李静 

研究负责人:

刘芳/李静 

Applicant:

Li Jing 

Study leader:

Liu Fang/Li Jing 

申请注册联系人电话:

Applicant telephone:

+86 151 9664 0746

研究负责人电话:

Study leader's
telephone:

+86 151 9664 0746

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

971999462@qq.com

研究负责人电子邮件:

Study leader's E-mail:

971999462@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市锦江区成龙大道一段1416号

研究负责人通讯地址:

四川省成都市锦江区成龙大道一段1416号

Applicant address:

No. 1416, Section 1, Chenglong Avenue, Jinjiang District, Chengdu City, Sichuan Province

Study leader's address:

No. 1416, Section 1, Chenglong Avenue, Jinjiang District, Chengdu City, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西第二医院

Applicant's institution:

West China Second Hospital of Sichuan University

研究负责人所在单位:

四川大学华西第二医院

Affiliation of the Leader:

West China Second Hospital of Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医学科研2026伦审批第(017)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西第二医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of West China Second Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-10 00:00:00

伦理委员会联系人:

吴雅迪

Contact Name of the ethic committee:

Wu Yadi

伦理委员会联系地址:

四川省成都市武侯区人民南路三段17号西部妇幼研究院

Contact Address of the ethic committee:

West Maternity and Child Research Institute, No. 17, Section 3, Renmin South Road, Wuhou District, Chengdu City, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8857 0104

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西第二医院

Primary sponsor:

West China Second Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市锦江区成龙大道一段1416号

Primary sponsor's address:

No. 1416, Section 1, Chenglong Avenue, Jinjiang District, Chengdu City, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西第二医院

具体地址:

锦江区成龙大道一段1416号

Institution
hospital:

West China Second Hospital of Sichuan University

Address:

No. 1416, Section 1, Chenglong Avenue, Jinjiang District, Chengdu City, Sichuan Province

经费或物资来源:

医院K基金(Z370)

Source(s) of funding:

Hospital K Fund (Z370)

研究疾病:

注意缺陷多动障碍  

Target disease:

Attention deficit hyperactivity disorder

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索不同模式重复经颅磁刺激(Repetitive Transcranial Magnetic Stimulation,rTMS )对未成年 ADHD 的临床疗效和机制  

Objectives of Study:

Exploring the Clinical Efficacy and Mechanisms of Repetitive Transcranial Magnetic Stimulation (rTMS) with Different Modes in Underage ADHD.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.法定监护人与研究参与者签署的知情同意书; 2.年龄8-18 岁 ; 3.通过美国精神病学协会《精神疾病诊断与统计手册》第5版(DSM-5)确诊ADHD; 4.治疗前患者病情稳定,药物剂量稳定>1 月,整个治疗过程中药物和其他治疗方法没有变化。

Inclusion criteria

1. The informed consent form signed by the legal guardian and the research participants; 2. Age range: 8-18 years old; 3. Diagnosed with ADHD through the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5); 4. The patient's condition was stable before treatment, and the drug dosage remained stable for more than 1 month. Throughout the entire treatment process, there were no changes in the medication or other treatment methods.

排除标准:

1.左撇子; 2.患有严重或不稳定的身体疾病; 3.有头部受伤或癫痫病史; 4.被诊断为精神发育迟滞、物质依赖或滥用(尼古丁和咖啡因除外)、双相情感障碍、强迫症、创伤后应激障碍、DSM-V 定义的饮食障碍等其他疾病; 5.体内有金属植入物或其他任何方式激活或控制的植入装置、植入的药物泵、心内线路; 6.服用苯二氮卓类药物; 7.半年内接受电抽搐等刺激; 8.视觉或听觉障碍。

Exclusion criteria:

1. Left handedness; 2. Suffering from serious or unstable physical illnesses; 3. History of head injury or epilepsy; 4. Diagnosed with mental retardation, substance dependence or abuse (excluding nicotine and caffeine), bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder, DSM-V defined eating disorders, and other illnesses; 5. Metal implants or any other means of activating or controlling implanted devices, implanted drug pumps, or intracardiac circuits within the body; 6. Taking benzodiazepine drugs; 7. Receive electrical convulsions and other stimuli within six months; 8. Visual or auditory impairments.

研究实施时间:

Study execute time:

From 2026-05-06 00:00:00 To 2027-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-10 00:00:00 To 2027-03-30 00:00:00

干预措施:

Interventions:

组别:

高频治疗组

样本量:

38

Group:

high-frequency treatment group

Sample size:

干预措施:

高频rTMS

干预措施代码:

Intervention:

high-frequency rTMS

Intervention code:

组别:

iTBS治疗组

样本量:

38

Group:

iTBS treatment group

Sample size:

干预措施:

iTBS

干预措施代码:

Intervention:

iTBS

Intervention code:

组别:

观察组

样本量:

38

Group:

observation group

Sample size:

干预措施:

观察4周+iTBS

干预措施代码:

Intervention:

4-week observation +iTBS

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西第二医院 

单位级别:

三甲 

Institution
hospital:

West China Second Hospital of Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

注意力测试

指标类型:

主要指标

Outcome:

Attention Test

Type:

Primary indicator

测量时间点:

测量方法:

IVA视听注意力测试

Measure time point of outcome:

Measure method:

IVA Audiovisual Attention Test

指标中文名:

治疗依从性

指标类型:

主要指标

Outcome:

treatment compliance

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

注意缺陷多动症状筛查

指标类型:

次要指标

Outcome:

Screening for Attention Deficit Hyperactivity Disorder Symptoms

Type:

Secondary indicator

测量时间点:

测量方法:

Swanson、Nolan 和 Pelham IV 评定量表(SNAP-IV)

Measure time point of outcome:

Measure method:

指标中文名:

认知功能

指标类型:

次要指标

Outcome:

cognitive function

Type:

Secondary indicator

测量时间点:

测量方法:

威斯康辛卡片分类测验

Measure time point of outcome:

Measure method:

Wisconsin Card Sorting Test

指标中文名:

社会功能

指标类型:

次要指标

Outcome:

Social function

Type:

Secondary indicator

测量时间点:

测量方法:

Weiss 功能障碍评估量表-父母表

Measure time point of outcome:

Measure method:

Weiss Disability Assessment Scale - Parent Scale

指标中文名:

不良事件

指标类型:

副作用指标

Outcome:

Adverse events

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑功能变化

指标类型:

主要指标

Outcome:

Brain function

Type:

Primary indicator

测量时间点:

测量方法:

近红外脑功能成像

Measure time point of outcome:

Measure method:

Near infrared brain functional imaging

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究实施人员李静在SPSS上产生随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Generate a random number table on SPSS by researcher Li Jing

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲(评估人员盲)

Blinding:

Single blind (evaluator blind)

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan, http://www.medresman.org.cn/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn/login.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-23 10:45:09